Metraipolis › archive › dc_e29b68807e7e
Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study — Europe PMC PMID:42136633
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42136633
- DOI
- 10.3389/fimmu.2026.1750735
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T23:06:36.496Z
- SHA-256 of the archived text
774cd1b608d565909f2721b1e3a63070094f2ef92a4f9627dcc4736cbb182803- Stable URL of this page
https://metraipolis.com/documento/dc_e29b68807e7e
How to cite
Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study — Europe PMC PMID:42136633 — Europe PMC (en), https://europepmc.org/article/MED/42136633 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e29b68807e7e (Metraipolis archive dc_e29b68807e7e, sha256 774cd1b608d565909f2721b1e3a63070094f2ef92a4f9627dcc4736cbb182803)
BibTeX
@misc{dce29b68807e7e,
title = {Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study — Europe PMC PMID:42136633},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42136633},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e29b68807e7e; sha256 774cd1b608d565909f2721b1e3a63070094f2ef92a4f9627dcc4736cbb182803},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42136633. Agents can read the archived copy with the MCP tool read_document.